Revenue → Gross profit: $14.872BPharmaceutical → Revenue: $13.562BMedical devices → Revenue: $7.821BRevenue → Cost of revenue: $6.511BGross profit → Operating profit: $5.909BGross profit → SG&A: $5.257BOperating profit → Net profit: $4.823BOncology → Pharmaceutical: $4.814BImmunology → Pharmaceutical: $4.246BGross profit → R&D: $3.542BSurgery → Medical devices: $2.416BOrthopaedics → Medical devices: $2.340BCardiovascular → Medical devices: $1.807BNeuroscience → Pharmaceutical: $1.803BVision → Medical devices: $1.258BOperating profit → Tax: $1.086BPulmonary → Pharmaceutical: $1.049BOther pharma → Pharmaceutical: $0.829BInfectious diseases → Pharmaceutical: $0.821BOther → Net profit: $0.322BInterest → Net profit: $0.209BGross profit → Restructuring: $0.164BImmunology: $4.246BPharmaceutical: $13.562BInfectious diseases: $0.821BNeuroscience: $1.803BOncology: $4.814BPulmonary: $1.049BOther pharma: $0.829BRevenue: $21.383BMedical devices: $7.821BCardiovascular: $1.807BOrthopaedics: $2.340BSurgery: $2.416BVision: $1.258BGross profit: $14.872BCost of revenue: $6.511BOperating profit: $5.909BSG&A: $5.257BR&D: $3.542BRestructuring: $0.164BTax: $1.086BInterest: $0.209BNet profit: $5.354BOther: $0.322Bcreated with SankeyArt.comImmunology$4.246BPharmaceutical$13.562B1% Y/YInfectious diseases$0.821BNeuroscience$1.803BOncology$4.814BPulmonary$1.049BOther pharma$0.829BRevenue$21.383B2% Y/YMedical devices$7.821B5% Y/YCardiovascular$1.807B20% Y/YOrthopaedics$2.340BSurgery$2.416BVision$1.258BGross profit$14.872B-47% Y/YCost of revenue$6.511B-3% Y/YOperating profit$5.909B-69% Y/YSG&A$5.257B7% Y/YR&D$3.542B3% Y/YRestructuring$0.164B26% Y/YTax$1.086BInterest$0.209BNet profit$5.354BOther$0.322BJohnson & Johnson Q1 FY24 Income Statement
2022
Q4 Full Year
2023
Q1 Q2 Q3 Q4 Full Year
2024
Q1 Q2 Q3